All News
Predicting Inflammatory Arthritis in At-Risk Persons
The Annals of Internal Medicine has published a predictive score to distinguish low-risk from high-risk inflammatory arthritis (IA) and who may benefit from risk stratification and preventive measures.
Read Article
Study of Veterans, Medicare, Medicaid RA pts (73070) pts, matched 1:10 w/ non-RA (639268) looked ataortic valve risk; RA pts have incr risk incident AS (adj HR 1.48), aortic valve surgery (aHR 1.34) & AS-related death (aHR 1.26). AS incidence=3.97/1000PYs https://t.co/rvA59hn6FE https://t.co/IS9jjuhYWv
Links:
Dr. John Cush RheumNow ( View Tweet)
Synovial T cells from 20 pts Rx w/ immune checkpoint inhibitors who developed ICI-arthritis compared w/ synovial T cells from RA & PsA pts - showing clonal expansion of activated effector CD38hi,CD127−, CD8 T cells, w/ incr type I IFN-assoc transcripts https://t.co/vw2sOGL6jQ https://t.co/uDlt9dH4mQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/08qOjVJE9A https://t.co/eH6oWsB1dT
Links:
Dr. John Cush RheumNow ( View Tweet)
The Importance of Knowing Which Entheses are Involved in PsA
Dr. Eric Ruderman discusses abstract POS0027 presented at EULAR 2023 in Milan, Italy.
https://t.co/nRJfNxwDF0 https://t.co/LUgLQTIUDD
Links:
Dr. John Cush RheumNow ( View Tweet)
New Full Length from A&R:
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns
https://t.co/5pzBfiZaNt
Created with https://t.co/L5O6lHuNSY https://t.co/HvDy4b1Bg3
Links:
ACR_Journals ACR_Journals ( View Tweet)
Retrospective study of 1877
pts. W/ granulomatosis with polyangiitis (GPA) on RTX found only 23% received TMP-SMX for a median of 141 days. Prophylaxis was assoc w/ prednisone use (OR 3.96), MTX use (OR 1.48), ICU care (OR 1.95), hospitalization(OR 1.56) https://t.co/JRUC8HUwJU
Links:
Dr. John Cush RheumNow ( View Tweet)
Pain in the Neck
https://t.co/JxNBJvlekM https://t.co/vaPSDK2vHQ
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-23 Inhibitor Performance in Psoriatic Disease
A single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
https://t.co/J3HIDBguj1 https://t.co/uqYf0Bdh0n
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown.
https://t.co/yNQkEwRT3W https://t.co/YG7uBpDrPP
Links:
Dr. John Cush RheumNow ( View Tweet)
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/iPhecsJeJX https://t.co/0TIy2hsPC1
Links:
Dr. John Cush RheumNow ( View Tweet)
Link Between Vitamin D and Psoriasis Severity
More than 8M people in the US experience psoriasis-a person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date.
https://t.co/bHnYn87wQS https://t.co/JsloVaxHd4
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid vasculitis (RV) metanalysis: RV decreased sincefrom 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/O3G4CS1pdx https://t.co/I2RVKR20lX
Links:
Dr. John Cush RheumNow ( View Tweet)
Voclosporin in SLE - Long-Term Safety and Efficacy
The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.
https://t.co/YmKLuhyCVG https://t.co/X2u9iCckt7
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR/ACR Guidance on HLH/MAS
A EULAR/ACR task force has established evidence based, up-to-date guidance, and expert opinion on the evaluation, management and monitoring of patients with HLH and MAS.
https://t.co/ZQQ75pyvAX https://t.co/t6lj5XaAwB
Links:
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitors Reduce Gout Flares and CV Events
A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations.
https://t.co/XCh7ulamwU https://t.co/dbOAtaflmb
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/8U6DHbJybE https://t.co/e45KCd5gBL
Links:
Dr. John Cush RheumNow ( View Tweet)
MMWR: Arthritis Among Children and Adolescents
The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.
https://t.co/S1dG60jJ1J https://t.co/rKQ64sopl2
Links:
Dr. John Cush RheumNow ( View Tweet)
RNase Treatment of Autoimmune Disorders
U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders.
https://t.co/RuXV3uAVz7 https://t.co/rWaKlmPnEe
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofactitinib in PsA & RA: Nine Year Safety Data
A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.
https://t.co/erBi7JJtCY https://t.co/9tU361FkfU
Links:
Dr. John Cush RheumNow ( View Tweet)